News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cyclacel Pharmaceuticals, Inc. (CYCC) Release: Independent Investigators Present Non-Clinical Data Providing Rationale For Sapacitabine Combination Treatment With Bcr-Abl Inhibitors In CML


4/10/2014 7:51:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BERKELEY HEIGHTS, N.J., April 10, 2014 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that independent investigators reported non-clinical data supporting the combination potential of Cyclacel's oral sapacitabine with Bcr-Abl inhibitors, including imatinib and ponatinib, in chronic myeloid leukemia (CML) cell lines. The data were reported in a poster presentation at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) held April 5-9, 2014 in San Diego.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES